Questioning the Pathogenic Role of the GLA p.Ala143Thr “Mutation” in Fabry Disease: Implications for Screening Studies and ERT
Open Access
- 29 July 2012
- book chapter
- Published by Springer Nature
- Vol. 8, 101-108
Abstract
Fabry disease is an X-linked inborn error of glycosphingolipid metabolism caused by quantitative or qualitative defects in the lysosomal enzyme alfa-Galactosidase A (aGAL A), ultimately resulting in vital organ dysfunction. Mainly the kidneys, the heart, and the central nervous system are involved. While the classical phenotype of Fabry disease is readily recognizable, screening studies have identified clinical variants. Here, we report the phenotype associated with the GLA p.Ala143Thr (c.427G>A) mutation in 12 patients aged 42–83 years. None of the patients had classical Fabry signs or symptoms as angiokeratoma, hypohidrosis, acroparesthesia, or cornea verticillata. Possible Fabry manifestations were renal failure (5/12), stroke (7/12), and left ventricular hypertrophy (5/12), but these were not necessarily attributable to the p.Ala143Thr mutation, as a cardiac biopsy in one female and left ventricular hypertrophy and kidney biopsies in two males with renal failure and microalbuminuria lacked Gb-3 deposits. The literature data on this mutation as well as data collected in the Fabry Outcome Survey (FOS) database confirm these findings. The association of renal failure, stroke, and left ventricular hypertrophy with this mutation could be the result of selection bias, as most patients were detected in screening studies. We conclude that care should be taken with attribution of vital organ dysfunction to GLA sequence alterations. In case of the p.Ala143Thr mutation, and possibly also other mutations associated with an attenuated phenotype, diagnostic tools such as biopsy and imaging should critically evaluate the relation of end-organ failure with Fabry disease, as this has important consequences for enzyme replacement therapy.Keywords
This publication has 20 references indexed in Scilit:
- Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry DiseasePLOS ONE, 2012
- A view on sphingolipids and diseaseChemistry and Physics of Lipids, 2011
- Fabry or not Fabry – a question of ascertainmentEuropean Journal of Human Genetics, 2011
- Belgian Fabry StudyStroke, 2010
- High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese PopulationCirculation: Cardiovascular Genetics, 2009
- Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic CardiomyopathyJACC, 2007
- Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis populationNephrology Dialysis Transplantation, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyNew England Journal of Medicine, 1995
- Fabry's Disease: Alpha-Galactosidase DeficiencyScience, 1970